Leber Hereditary Optic Neuropathy

Leber Hereditary Optic Neuropathy (LHON) is a rare genetic eye disease that causes a sudden and painless loss of central vision. It usually affects young adults, most commonly men in their teens or twenties. The condition typically starts with blurry or cloudy vision in one eye, and within a few weeks or months, the second eye also becomes affected. This loss of central vision makes it very difficult to read, drive, or recognize faces, although peripheral (side) vision usually remains intact. LHON is caused by changes (mutations) in the DNA of mitochondria, which are the energy-producing powerhouses of our cells. Because these mutations are passed down only from mothers, women with the gene change can pass it to all their children, but men cannot pass it on. Not everyone who inherits the mutated gene will lose their vision; in fact, many people carry the gene without ever having symptoms. However, certain lifestyle factors, especially smoking and heavy alcohol use, can significantly increase the risk of vision loss in people who carry the gene. Currently, there is no complete cure for LHON, and most people with the condition will experience permanent, severe vision loss. However, there are supportive treatments and visual aids that can help patients adapt to their vision changes. A medication called idebenone has shown promise in helping some patients recover a portion of their vision if started early. Additionally, researchers are actively studying new treatments, including gene therapy, which may offer hope for restoring vision in the future. Patients and their families are strongly encouraged to seek genetic counseling and avoid smoking and excessive alcohol to protect their remaining vision.

Condition category: Optic Neuropathy

Prevalence: 1 in 27,000 to 1 in 50,000

Inheritance patterns: Mitochondrial

Age of onset: Second and third decades of life

Clinical overview: Leber Hereditary Optic Neuropathy (LHON) is a rare, maternally inherited mitochondrial genetic disorder characterized by bilateral, painless, subacute loss of central vision. It is the most common primary mitochondrial DNA (mtDNA) disease, predominantly affecting young adult males in their second or third decades of life. The condition is caused by point mutations in the mtDNA, most frequently m.11778G>A, m.3460G>A, and m.14484T>C, which affect subunits of Complex I of the mitochondrial respiratory chain. This leads to impaired cellular energy production and increased oxidative stress, resulting in the selective degeneration of retinal ganglion cells (RGCs) and their axons, particularly within the papillomacular bundle. Clinically, LHON typically presents with unilateral visual blurring that rapidly progresses to severe visual loss, with the fellow eye becoming involved sequentially within weeks to months. The hallmark visual field defect is a dense central or centrocecal scotoma, accompanied by profound dyschromatopsia. During the acute phase, funduscopic examination may reveal a classic triad of circumpapillary telangiectatic microangiopathy, pseudoedema of the optic disc, and an absence of leakage on fluorescein angiography. However, the fundus can appear normal in up to 20-40% of cases initially. As the disease progresses into the chronic phase, the acute fundus changes resolve, giving way to profound optic atrophy and severe thinning of the retinal nerve fiber layer (RNFL). Most patients are left with permanent, severe visual impairment, often meeting the criteria for legal blindness. While LHON is typically an isolated optic neuropathy, some patients may present with "LHON Plus" disease, exhibiting additional neurological or cardiac conduction abnormalities. Diagnosis relies on clinical recognition, characteristic optical coherence tomography (OCT) findings, and confirmation via molecular genetic testing. Management is largely supportive, though emerging therapies like idebenone and gene therapy offer potential avenues for visual recovery.

Patient and family guide: Leber Hereditary Optic Neuropathy (LHON) is a rare genetic eye disease that causes a sudden and painless loss of central vision. It usually affects young adults, most commonly men in their teens or twenties. The condition typically starts with blurry or cloudy vision in one eye, and within a few weeks or months, the second eye also becomes affected. This loss of central vision makes it very difficult to read, drive, or recognize faces, although peripheral (side) vision usually remains intact. LHON is caused by changes (mutations) in the DNA of mitochondria, which are the energy-producing powerhouses of our cells. Because these mutations are passed down only from mothers, women with the gene change can pass it to all their children, but men cannot pass it on. Not everyone who inherits the mutated gene will lose their vision; in fact, many people carry the gene without ever having symptoms. However, certain lifestyle factors, especially smoking and heavy alcohol use, can significantly increase the risk of vision loss in people who carry the gene. Currently, there is no complete cure for LHON, and most people with the condition will experience permanent, severe vision loss. However, there are supportive treatments and visual aids that can help patients adapt to their vision changes. A medication called idebenone has shown promise in helping some patients recover a portion of their vision if started early. Additionally, researchers are actively studying new treatments, including gene therapy, which may offer hope for restoring vision in the future. Patients and their families are strongly encouraged to seek genetic counseling and avoid smoking and excessive alcohol to protect their remaining vision.

Symptoms and clinical features: The primary symptom of Leber Hereditary Optic Neuropathy (LHON) is a painless, subacute, and progressive loss of central vision. It typically begins in one eye with a sensation of mist, fog, or blurring in the central visual field, accompanied by a fading of colors (dyschromatopsia). The second eye is usually affected sequentially within weeks to months, with 97% of patients having bilateral involvement within one year. The visual loss rapidly worsens over several months, reaching a nadir where visual acuity often drops to 20/200 or worse. Patients develop a dense central or centrocecal scotoma, severely impacting tasks like reading and facial recognition, though peripheral vision is generally spared. Rarely, patients may experience "LHON Plus" symptoms, including tremors, peripheral neuropathy, movement disorders, or cardiac arrhythmias.

Molecular pathology: Leber Hereditary Optic Neuropathy (LHON) is fundamentally a disorder of mitochondrial dysfunction caused by point mutations in the mitochondrial DNA (mtDNA). The three primary pathogenic variants—m.11778G>A in the MT-ND4 gene, m.3460G>A in the MT-ND1 gene, and m.14484T>C in the MT-ND6 gene—account for approximately 90% of all cases. These genes encode essential subunits of NADH:ubiquinone oxidoreductase (Complex I), the first and largest enzyme complex of the mitochondrial respiratory chain. The mutations lead to structural alterations in Complex I, resulting in impaired electron transport and a subsequent decrease in adenosine triphosphate (ATP) production. This bioenergetic defect is accompanied by an increase in the generation of reactive oxygen species (ROS), leading to oxidative stress. Retinal ganglion cells (RGCs), particularly the small parvocellular RGCs that form the papillomacular bundle, are highly metabolically active and exquisitely sensitive to this energy depletion and oxidative damage. The combination of ATP deficiency and ROS-mediated toxicity triggers apoptosis in these vulnerable RGCs. The selective degeneration of the papillomacular bundle, which serves central vision, explains the characteristic clinical presentation of profound central visual loss. The progressive loss of RGCs and their axons ultimately leads to optic nerve atrophy. The variable penetrance of the disease is thought to be influenced by the degree of heteroplasmy, mitochondrial haplogroups, nuclear genetic modifiers, and environmental stressors that further compromise mitochondrial function.

Genetics: Leber Hereditary Optic Neuropathy (LHON) is caused by mutations in the mitochondrial DNA (mtDNA) and is strictly transmitted through maternal inheritance. Because mitochondria are inherited exclusively from the mother's ovum, a female carrying an LHON-causing mutation will pass it to all her children, whereas an affected male cannot transmit the mutation to his offspring. The disease is primarily associated with three common point mutations in the mtDNA: m.11778G>A (MT-ND4), m.3460G>A (MT-ND1), and m.14484T>C (MT-ND6), which together account for about 90% of cases. LHON exhibits incomplete penetrance and a marked sex bias. Not all individuals harboring a pathogenic mutation will develop symptoms. It is estimated that up to 50% of male carriers and about 10% of female carriers will experience vision loss. This variable penetrance suggests the involvement of secondary factors, including mitochondrial heteroplasmy (the proportion of mutant to wild-type mtDNA within cells), nuclear genetic modifiers (such as X-linked susceptibility genes), and environmental triggers like smoking and excessive alcohol consumption, which can increase oxidative stress and precipitate vision loss. Genetic counseling is essential for affected families. It is crucial to inform patients that female carriers will transmit the mutation to all their children, while male carriers will not pass it on. Asymptomatic carriers should be advised to avoid environmental risk factors, particularly smoking and heavy alcohol intake, to potentially reduce their risk of developing the clinical phenotype.

Diagnostic evaluation: Diagnosis of Leber Hereditary Optic Neuropathy (LHON) is primarily based on clinical findings and confirmed by molecular genetic testing. Clinical evaluation includes a detailed neuro-ophthalmologic examination with assessment of visual acuity, color vision, and visual fields, which typically reveal central or centrocecal scotomas. Dilated fundus examination during the acute phase may show the classic triad of circumpapillary telangiectatic microangiopathy, pseudoedema of the retinal nerve fiber layer (RNFL), and absence of leakage on fluorescein angiography. Optical coherence tomography (OCT) is crucial for detecting early RNFL thickening and subsequent thinning, particularly in the temporal quadrant (papillomacular bundle). Definitive diagnosis requires targeted genetic testing of mitochondrial DNA (mtDNA) to identify one of the three primary pathogenic variants: m.11778G>A, m.3460G>A, or m.14484T>C, which account for approximately 90% of cases. If these are negative, complete sequencing of the mitochondrial genome may be indicated. Magnetic resonance imaging (MRI) of the brain and orbits is recommended to rule out compressive lesions or demyelinating diseases like multiple sclerosis, though it may show optic nerve enhancement or chiasmal enlargement in LHON.

Differential diagnosis: Optic Neuritis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Dominant Optic Atrophy, Toxic/Nutritional Optic Neuropathy, Compressive Optic Neuropathy, Ischemic Optic Neuropathy

Natural history: The natural history of Leber Hereditary Optic Neuropathy (LHON) typically progresses through distinct clinical phases. The asymptomatic phase involves mutation carriers who may have normal vision but exhibit subtle fundus changes or subclinical retinal nerve fiber layer (RNFL) thickening. The acute/subacute phase begins with painless, unilateral blurring of central vision, followed by involvement of the second eye within weeks to months (usually within one year). During this phase, visual acuity rapidly deteriorates, reaching a nadir within 4 to 6 months, accompanied by enlarging central scotomas and characteristic fundus changes like pseudoedema and peripapillary telangiectasia. The dynamic phase occurs 6 to 12 months after onset, where visual fields and OCT measurements plateau. Finally, the chronic phase (after 12 months) is characterized by severe, usually irreversible visual impairment, optic atrophy, and marked thinning of the RNFL. While most patients remain legally blind, a small percentage, particularly those with the m.14484T>C mutation, may experience some spontaneous visual recovery years later.

Management and treatment research: ### Current management and supportive care There is no cure for Leber hereditary optic neuropathy (LHON), a mitochondrial condition that damages retinal ganglion cells and the optic nerve. It usually causes painless, subacute loss of central vision. Care focuses on preserving independence, monitoring vision, and reducing factors that may place additional stress on mitochondria, the parts of cells that produce energy. Management may include: - Regular follow-up with an ophthalmologist or neuro-ophthalmologist and prompt evaluation of new vision changes - Low-vision services, including magnifiers, electronic reading devices, screen-accessibility tools, and orientation and mobility training - Vision rehabilitation and occupational therapy to support daily activities, education, and work - Genetic counseling for affected individuals and maternal relatives. LHON is usually caused by variants in mitochondrial DNA and is generally inherited through the maternal line. - Avoiding smoking and heavy alcohol use. These exposures can affect mitochondrial function and have been associated with a greater risk of vision loss in people who carry LHON-associated variants. ### Approved therapies **Idebenone** is a synthetic compound related to coenzyme Q10 that may support mitochondrial energy production and reduce oxidative stress. It is authorized for LHON in some countries, including some European countries, but is not approved by the U.S. Food and Drug Administration for LHON. Studies such as RHODOS and LEROS suggest that idebenone may help some people stabilize or recover vision, particularly when treatment begins relatively early after vision loss starts. A commonly used regimen is 900 mg daily in divided doses, but the dose and duration should be individualized by an ophthalmologist or mitochondrial-disease specialist. Availability and coverage vary by country. ### Investigational therapies #### Gene therapy Several gene-therapy approaches are being studied for LHON caused by the common **m.11778G>A variant in the MT-ND4 gene**. These treatments generally use *allotopic expression*, in which a functional copy of the ND4 gene is delivered to the cell nucleus and designed to produce a protein that can enter mitochondria. - **Lenadogene nolparvovec (GS010)** is being evaluated in a recruiting Phase 2 study of bilateral intravitreal (into-the-eye) injections at two dose levels (**NCT07303296**). - A Phase 3 randomized, sham-controlled study is active but not recruiting for LHON associated with an ND4 mutation (**NCT07406854**). These treatments remain investigational and are not established standard care. #### Metabolic approaches **Glycerol tributyrate** is being studied in a Phase 1/2 basket trial for people with MELAS or LHON (**NCT06792500**). The study is not yet recruiting. Its safety and effectiveness for LHON have not been established. #### Cell-based approaches A recruiting study, **NCT03011541**, is evaluating stem-cell–based ophthalmic treatment approaches. Stem cell treatments have not been established as effective treatment for LHON. People considering such studies should carefully review eligibility criteria, procedures, potential risks, follow-up requirements, and regulatory oversight. ### Clinical trial participation Clinical trials may provide access to investigational treatments, but they do not guarantee benefit and may involve unknown risks. Research participation can also include studies of retinal structure and function (**NCT03475173**) and patient registries or biorepositories, including the Inherited Retinal Degenerative Disease Registry (**NCT02435940**) and the North American Mitochondrial Disease Consortium registry and biorepository (**NCT01694940**). These studies can help researchers better understand LHON and support future treatment development.

Outlook: The prognosis for visual recovery in Leber Hereditary Optic Neuropathy (LHON) is generally poor, with most patients experiencing permanent, severe visual impairment and remaining legally blind. Visual acuity typically deteriorates to counting fingers or worse. However, the likelihood of spontaneous visual recovery varies significantly depending on the specific mitochondrial DNA mutation. The m.14484T>C mutation has the best prognosis, with up to 37-58% of patients experiencing some visual improvement, whereas the m.11778G>A and m.3460G>A mutations have much lower recovery rates (around 11-22%). Early age of onset and a subacute presentation may also predict better outcomes. Despite severe central vision loss, peripheral vision is usually preserved, allowing patients to navigate independently.

Epidemiology: Leber Hereditary Optic Neuropathy (LHON) is the most common inherited mitochondrial disorder, with an estimated prevalence ranging from 1 in 27,000 to 1 in 50,000 worldwide. It exhibits a strong male predominance, with males being four to five times more likely to be affected than females. The peak age of onset is in the second and third decades of life, typically between 15 and 35 years, although childhood and late-onset cases have been reported. While the causative mitochondrial DNA mutations are maternally inherited and present in all maternal relatives, penetrance is incomplete. Approximately 50% of male carriers and 10% of female carriers will eventually develop vision loss, suggesting that additional genetic, hormonal, or environmental factors, such as smoking and alcohol consumption, play a role in disease expression.

Selected references: 1. Yu-Wai-Man P, Chinnery PF. Leber Hereditary Optic Neuropathy. GeneReviews. 2000 (Updated 2021). 2. Shemesh A, et al. Leber Hereditary Optic Neuropathy (LHON). StatPearls. 2024. 3. Newman NJ, et al. Understanding the molecular basis and pathogenesis of hereditary optic neuropathies. The Lancet Neurology. 2023. 4. La Morgia C, et al. Recognizing Leber's Hereditary Optic Neuropathy to avoid delayed diagnosis. Frontiers in Neurology. 2024. 5. Biousse V, et al. Outcomes of lenadogene nolparvovec gene therapy in LHON. JAMA Ophthalmology. 2024.